









市場行情
/
股票
/
nasdaq-jazz
/

Jazz Pharmaceuticals PLC

JAZZ

166.990USD

+0.990+0.60%

收盤 12/19, 16:00（美東）報價延遲15分鐘

10.14B總市值

虧損本益比TTM



Jazz Pharmaceuticals PLC

166.990

+0.990+0.60%

概覽公司財務分析

概覽

公司

財務

分析

關於 Jazz Pharmaceuticals PLC 公司

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Jazz Pharmaceuticals PLC簡介



公司代碼JAZZ

公司名稱Jazz Pharmaceuticals PLC

上市日期Jan 18, 2012

CEOGala (Renee D)

員工數量2800

證券類型Ordinary Share

年結日Jan 18

公司地址Fifth Floor, Waterloo Exchange

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Ireland

郵編- -

電話35316347800

網址https://www.jazzpharma.com/

公司代碼JAZZ

上市日期Jan 18, 2012

CEOGala (Renee D)

Jazz Pharmaceuticals PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

292.32K

-5.03%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.12K

-0.17%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

24.12K

-22.89%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+13.93%

Ms. Anne O'Riordan

Independent Director

12.77K

+15.38%

Ms. Samantha Pearce

Executive Vice President, Chief Commercial Officer

9.24K

-5.88%

Ms. Jennifer E. Cook

Independent Director

7.11K

+31.50%

名稱

名稱/職務

職務

持股

持股變動

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

292.32K

-5.03%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.12K

-0.17%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

24.12K

-22.89%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

其他

149.32M

14.28%

地區USD

名稱

營收

佔比

United States

936.28M

89.54%

Europe

82.76M

7.91%

All Others

26.67M

2.55%

業務

地區

業務USD

名稱

營收

佔比

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

其他

149.32M

14.28%

股東統計

更新時間: 12月4日週四

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.13%

其他

69.06%

持股股東

佔比

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.13%

其他

69.06%

股東類型

持股股東

佔比

Investment Advisor

50.91%

Investment Advisor/Hedge Fund

34.93%

Hedge Fund

10.56%

Research Firm

3.49%

Individual Investor

3.02%

Pension Fund

1.77%

Venture Capital

1.30%

Bank and Trust

0.85%

Sovereign Wealth Fund

0.09%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1197

64.03M

105.38%

-5.21M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

6.07M

10%

+73.43K

+1.22%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.22M

8.61%

+11.23K

+0.22%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.18%

+209.41K

+8.99%

Jun 30, 2025

Capital World Investors

2.54M

4.19%

+616.73K

+31.99%

Jun 30, 2025

LSV Asset Management

2.55M

4.21%

+87.58K

+3.55%

Jun 30, 2025

State Street Investment Management (US)

1.94M

3.19%

-31.20K

-1.59%

Jun 30, 2025

EcoR1 Capital, LLC

1.71M

2.81%

Jun 30, 2025

JP Morgan Asset Management

1.55M

2.55%

+46.92K

+3.12%

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

1.63M

2.69%

+297.95K

+22.39%

Jun 30, 2025

Columbia Threadneedle Investments (US)

1.54M

2.54%

+186.67K

+13.80%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Cambria Cannabis ETF

4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

3.11%

iShares U.S. Pharmaceuticals ETF

3.08%

Invesco Pharmaceuticals ETF

2.94%

State Street SPDR S&P Pharmaceuticals ETF

2.83%

Abacus FCF International Leaders ETF

2.69%

First Trust NASDAQ Pharmaceuticals ETF

2.51%

Clough Hedged Equity ETF

2.4%

Alger Russell Innovation ETF

2.12%

VictoryShares Small Cap Free Cash Flow ETF

1.77%

Cambria Cannabis ETF

佔比4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比3.11%

iShares U.S. Pharmaceuticals ETF

佔比3.08%

Invesco Pharmaceuticals ETF

佔比2.94%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.83%

Abacus FCF International Leaders ETF

佔比2.69%

First Trust NASDAQ Pharmaceuticals ETF

佔比2.51%

Clough Hedged Equity ETF

佔比2.4%

Alger Russell Innovation ETF

佔比2.12%

VictoryShares Small Cap Free Cash Flow ETF

佔比1.77%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Jazz Pharmaceuticals PLC的前五大股東是誰？



Jazz Pharmaceuticals PLC的前五大股東如下：
The Vanguard Group, Inc.
持有股份：6.07M
佔總股份比例：10.00%。
BlackRock Institutional Trust Company, N.A.
持有股份：5.22M
佔總股份比例：8.61%。
Dimensional Fund Advisors, L.P.
持有股份：2.54M
佔總股份比例：4.18%。
Capital World Investors
持有股份：2.54M
佔總股份比例：4.19%。
LSV Asset Management
持有股份：2.55M
佔總股份比例：4.21%。